Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Medline Inc.
Bear Case (25th pct.)
-42.1% vs price
Base Case (Median)
-22.3% vs price
Bull Case (75th pct.)
-6.0% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $30.83 | -13.4% | High (40%) |
| PE Comparable | $19.31 | -45.8% | Medium (25%) |
| Graham Number | $15.57 | -56.3% | Medium (40%) |
| EV/EBITDA | $24.49 | -31.2% | Medium (20%) |
| EV/FCF | $34.36 | -3.5% | Medium (20%) |
| Earnings Power Value | $38.97 | 9.4% | Medium (50%) |
Based on 6 out of 7 methods, MDLN appears overvalued at the current price of $35.61. The base case fair value of $27.66 implies 22.3% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.